Switch theme
Sign up to access all valuation multiples
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
1993
74
LTM Revenue $23.2M
Last FY EBITDA -$4.1M
$33.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Compugen has a last 12-month revenue (LTM) of $23.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Compugen achieved revenue of $8.0M and an EBITDA of -$4.1M.
Compugen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Compugen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.2M | XXX | $8.0M | XXX | XXX | XXX |
| Gross Profit | $15.7M | XXX | $5.7M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$4.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -52% | XXX | XXX | XXX |
| EBIT | -$21.2M | XXX | -$4.3M | XXX | XXX | XXX |
| EBIT Margin | -91% | XXX | -53% | XXX | XXX | XXX |
| Net Profit | -$19.4M | XXX | -$4.1M | XXX | XXX | XXX |
| Net Margin | -84% | XXX | -51% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Compugen's stock price is ILS 5 (or $1).
Compugen has current market cap of ILS 475M (or $136M), and EV of ILS 118M (or $33.7M).
See Compugen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33.7M | $136M | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Compugen has market cap of $136M and EV of $33.7M.
Compugen's trades at 4.2x EV/Revenue multiple, and -8.2x EV/EBITDA.
Equity research analysts estimate Compugen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Compugen has a P/E ratio of -7.0x.
See valuation multiples for Compugen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $136M | XXX | $136M | XXX | XXX | XXX |
| EV (current) | $33.7M | XXX | $33.7M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -8.2x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -7.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.0x | XXX | -33.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCompugen's last 12 month revenue growth is -7%
Compugen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Compugen's rule of 40 is -45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Compugen's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Compugen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | 97% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -52% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -45% | XXX | -59% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 89% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Compugen acquired XXX companies to date.
Last acquisition by Compugen was XXXXXXXX, XXXXX XXXXX XXXXXX . Compugen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Compugen founded? | Compugen was founded in 1993. |
| Where is Compugen headquartered? | Compugen is headquartered in Israel. |
| How many employees does Compugen have? | As of today, Compugen has 74 employees. |
| Who is the CEO of Compugen? | Compugen's CEO is Dr. Anat Cohen-Dayag, PhD. |
| Is Compugen publicy listed? | Yes, Compugen is a public company listed on TAE. |
| What is the stock symbol of Compugen? | Compugen trades under CGEN ticker. |
| When did Compugen go public? | Compugen went public in 2002. |
| Who are competitors of Compugen? | Similar companies to Compugen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Compugen? | Compugen's current market cap is $136M |
| What is the current revenue of Compugen? | Compugen's last 12 months revenue is $23.2M. |
| What is the current revenue growth of Compugen? | Compugen revenue growth (NTM/LTM) is -7%. |
| What is the current EV/Revenue multiple of Compugen? | Current revenue multiple of Compugen is 1.5x. |
| Is Compugen profitable? | Yes, Compugen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
